Avoiding immune destruction is a hallmark of cancer. Over the past few years, significant
advances have been made in understanding immune dysfunction and immunosuppression …

Cancer/testis (CT) antigens are a category of tumor antigens with normal expression
restricted to male germ cells in the testis but not in adult somatic tissues. In some cases, CT …

Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable.
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T …

Cancer testis antigens (CTA) are a large family of tumor-associated antigens expressed in
human tumors of different histological origin, but not in normal tissues except for testis and …

Adoptive T cell therapy has achieved dramatic success in a clinic, and the Food and Drug
Administration approved two chimeric antigen receptor-engineered T cell (CAR-T) therapies …

The first tumor‐specific shared antigens and the cancer‐germline genes that code for these
antigens were identified with antitumor cytolytic T lymphocytes obtained from cancer …

Autologous peripheral blood stem cell (PBSC)–supported high-dose melphalan is now
considered standard therapy for myeloma, at least for younger patients. The markedly …

The MAGE gene family is characterized by a conserved domain (MAGE Homology Domain).
A subset of highly homologous MAGE genes (group A; MAGE-A) belong to the chromosome …

Despite significant advances in the treatment of head and neck squamous cell carcinoma
(HNSCC), the survival rate has not changed in the last decades. Therefore, the development …

This study in patients with relapsed, refractory, or high-risk multiple myeloma (MM)
evaluated the safety and activity of autologous T cells engineered to express an affinity …